Georgina Arrambide

Sep 3, 2024 | nature.com | Ruth Geraldes |Georgina Arrambide |Alex Rovira |Hans Lassmann |Patrick Waters |Declan T. Chard | +6 more

AbstractMyelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated demyelinating disease that is challenging to differentiate from multiple sclerosis (MS), as the clinical phenotypes overlap, and people with MOGAD can fulfil the current MRI-based diagnostic criteria for MS. In addition, the MOG antibody assays that are an essential component of MOGAD diagnosis are not standardized.

Dec 18, 2023 | touchneurology.com | Georgina Arrambide

Multiple Sclerosis Read Time: 5 mins Copy Link Published Online: Dec 18th 2023 touchREVIEWS in Neurology. 2024;20(1):Online ahead of journal publication Authors: Georgina Arrambide Quick Links: Overview Multiple sclerosis presents various challenges, leading to an exploration of fluid biomarkers that could provide insights into disease diagnosis, prognosis and treatment response.

Oct 23, 2023 | neurologylive.com | Georgina Arrambide

WATCH TIME: 5 minutes"One of the key notes we’re going to have to know is understanding what a typical symptom for MS is and what isn’t. Because then that’s going to guide us through the rest of the process.